ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026
SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


